The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer
KD Tew, Y Manevich, C Grek, Y Xiong, J Uys… - Free Radical Biology …, 2011 - Elsevier
Glutathione S-transferase P is abundantly expressed in some mammalian tissues,
particularly those associated with malignancies. While the enzyme can catalyze thioether …
particularly those associated with malignancies. While the enzyme can catalyze thioether …
[HTML][HTML] Molecular genetics of abnormal redox homeostasis in type 2 diabetes mellitus
I Azarova, A Polonikov, E Klyosova - International Journal of Molecular …, 2023 - mdpi.com
Numerous studies have shown that oxidative stress resulting from an imbalance between
the production of free radicals and their neutralization by antioxidant enzymes is one of the …
the production of free radicals and their neutralization by antioxidant enzymes is one of the …
Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors
J Oldenburg, SM Kraggerud, M Cvancarova… - Journal of clinical …, 2007 - ascopubs.org
Purpose Cisplatin, a cornerstone of combination chemotherapy in the treatment of testicular
cancer, induces hearing impairment with considerable interindividual variations. These …
cancer, induces hearing impairment with considerable interindividual variations. These …
Genetic Variants of Glutathione S-Transferase as Possible Risk Factors for Hepatocellular Carcinoma: A HuGE Systematic Review and Meta-Analysis
The authors performed a systematic review and meta-analysis to determine the effect of
polymorphisms in genes encoding glutathione S-transferases (GST s), phase II isoenzymes …
polymorphisms in genes encoding glutathione S-transferases (GST s), phase II isoenzymes …
[HTML][HTML] Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and-M1, a retrospective cross …
J Oldenburg, SM Kraggerud, M Brydøy… - Journal of translational …, 2007 - Springer
Background To assess the impact of polymorphisms in Glutathione S-transferase (GST)-P1,-
M1, and-T1 on self-reported chemotherapy-induced long-term toxicities in testicular cancer …
M1, and-T1 on self-reported chemotherapy-induced long-term toxicities in testicular cancer …
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
MT Voso, V Santini, C Finelli, P Musto, E Pogliani… - Clinical cancer …, 2009 - AACR
Purpose: Epigenetic changes play a role and cooperate with genetic alterations in the
pathogenesis of myelodysplastic syndromes (MDS). We conducted a phase II multicenter …
pathogenesis of myelodysplastic syndromes (MDS). We conducted a phase II multicenter …
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment
C Ekhart, S Rodenhuis, PHM Smits, JH Beijnen… - Cancer treatment …, 2009 - Elsevier
A wide interindividual variability in survival after cancer treatment is observed. This is
attributable to many factors, including tumour and patient related factors. Genetic …
attributable to many factors, including tumour and patient related factors. Genetic …
Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma
N Barahmani, S Carpentieri, XN Li, T Wang… - Neuro …, 2009 - academic.oup.com
Glutathione S-transferases (GSTs) are polymorphic enzymes that catalyze the glutathione
conjugation of alkylating agents, platinum compounds, and free radicals formed by radiation …
conjugation of alkylating agents, platinum compounds, and free radicals formed by radiation …
Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy
Cyclophosphamide is a cornerstone in the treatment of many pediatric and adult
malignancies, as well as in the treatment of refractory autoimmune conditions. Genetic …
malignancies, as well as in the treatment of refractory autoimmune conditions. Genetic …
[HTML][HTML] Prognostic factors in hodgkin lymphoma
A Cuccaro, F Bartolomei, E Cupelli, E Galli… - … journal of hematology …, 2014 - ncbi.nlm.nih.gov
Hodgkin lymphoma (HL) is among the neoplastic diseases that has the best long-term
outcome after cytotoxic treatment. Cure rates approach 80–90%; however, 15–20% of …
outcome after cytotoxic treatment. Cure rates approach 80–90%; however, 15–20% of …